SCHEMBL497035

SCHEMBL497035

CC1C[C@H]2CN(C(=O)OC(C)(C)C)[C@H](CNC(=O)c3cn4ccsc4n3)[C@H]2C1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
NAMPT P43490 4/20 0.34
TSHR P16473 3/20 0.33
TP53 P04637 5/20 0.33
MAPK10 P53779 1/20 0.33
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 2/20 0.32
USP2 O75604 1/20 0.32
METTL3 Q86U44 2/20 0.32
NPSR1 Q6W5P4 2/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HTR4 Q13639 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2442584 1.00 HCRTR1 (0.35) HCRTR1HCRTR2NAMPTTSHRTP53
SCHEMBL2931770 0.95 HCRTR1 (0.38) HCRTR1HCRTR2NAMPTTSHRTP53
SCHEMBL2931772 0.95 HCRTR1 (0.38) HCRTR1HCRTR2NAMPTTSHRTP53
SCHEMBL2450569 0.82 HCRTR1 (0.49) HCRTR1HCRTR2
SCHEMBL496259 0.82 HCRTR1 (0.49) HCRTR1HCRTR2
SCHEMBL496343 0.81 HCRTR1 (0.35) HCRTR1HCRTR2NAMPTHPGDKDM4E
SCHEMBL2930755 0.77 HCRTR1 (0.54) HCRTR1HCRTR2
SCHEMBL3415424 0.77 HCRTR1 (0.54) HCRTR1HCRTR2
SCHEMBL2930753 0.77 HCRTR1 (0.54) HCRTR1HCRTR2
SCHEMBL1340238 0.77 HCRTR1 (0.54) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106215-B2 3-aza-bicyclo[3.3.0]octane compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-01-31 US disclosed
US-8106215-B2 3-aza-bicyclo[3.3.0]octane compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-01-31 US disclosed
US-8106215-B2 3-aza-bicyclo[3.3.0]octane compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-01-31 US disclosed
EP-2164847-B1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2011-09-14 EP disclosed
US-20100184808-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-22 US disclosed
US-20100184808-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-22 US disclosed
US-20100184808-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184808-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS HCRTR2, HCRTR1, OXTR HCRTR1 2/4885HCRTR2 1/4885NAMPT 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.